Danaher (DHR) official guidance

| Adjusted diluted net earnings per common share from continuing operations (non-GAAP) | | | $8.57 - $8.62 |

Additionally, given our second quarter earnings beat and the earlier than anticipated completion of the Masimo acquisition, we're raising our full-year adjusted diluted net EPS guidance to a range of $8.45-$8.60, versus our previous range of $8.35-$8.55.

| Adjusted diluted net earnings per common share (non-GAAP) | | | $8.45 - $8.60 |

Additionally, given our strong Q1 performance, we're raising our full year adjusted diluted net EPS guidance to a range of $8.35-$8.55 versus our previous range of $8.35-$8.50.

| Adjusted diluted net earnings per common share (non-GAAP) | | | $8.35 - $8.55 | |

Additionally, we are initiating full-year adjusted diluted EPS guidance in the range of $8.35-$8.50.

| Adjusted diluted net earnings per common share (non-GAAP) | $8.35 - $8.50 |

| Adjusted operating profit margin (non-GAAP) | ~29.5 | % |

| Impact of respiratory testing | ~+150 basis points | +Low-single digit |

| Impact of respiratory testing | +2.5% | Flat | +Low-single digit |

| Respiratory testing sales N | ~$650 | ~$300 | ~$500 | ~$500 | ~$1,900 | | ~$500 | | ~$250 | | ~$350 | ~$400 | ~$1,500 |

| Amortization of acquisition-related intangible assets ($ in millions) | ~$(500) | | ~$(1,900) |

Danaher Corporation (the “Company”) does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $1.7 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which for the second quarter and full year 2026 is estimated to increase sales by 0.5% in both periods, assuming the currency exchange rates in effect as of March 27, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP.

| Biotechnology | +Mid-single digit | | +Mid-single digit |

| Biotechnology | +Mid-single digit | ~+6.0% |

| Biotechnology | +High-single digit | ~+6.0% |

| Diagnostics | Flat | | +Up slightly |

| Diagnostics | Flat | +Low-single digit |

| Diagnostics | -Low-single digit | +Low-single digit |

| Life Sciences | +3.0% - +4.0% | | +3.0% - +4.0% |

| Life Sciences | +Up slightly | +Up slightly |

| Life Sciences | Flat/ -Low-single digit | Flat |

| Total Company | +2.0% - +3.0% | +Mid-single digit | +3.0% - +4.0% |

| Total Company | +Low-single digit | +3.0% - +6.0% |

| Total Company core sales growth (non-GAAP) | +Low-single digit | +3.0% - +6.0% |

| Total Company | +2.0% - +3.0% | +Mid-single digit | +3.0% - +4.0% |

| Core sales growth excluding respiratory testing (non-GAAP) | ~+5.0% | +Mid-single digit | +Mid-single digit |

| Core sales growth excluding respiratory testing (non-GAAP) | ~+5.0% | +Mid-single digit | +Mid-single digit |